Phage Therapeutics Inc.
This article was originally published in Start Up
Phage Therapeutics will combat bacterial infections with bacteriophage, a well-known class of viruses that infect bacteria and destroy them. PhageTx has been collecting genetically diverse bacteriophage specific for Staphylococcus aureus and S. epidermidis--the company's initial targets for therapy.
You may also be interested in...
Overcoming drug resistance is a key goal of development--but will anyone fund it?
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.